Study of XL418 in Adults With Solid Tumors
NCT00460278 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2008-06-04
Summary
The purpose of this study is to evaluate the safety and tolerability of XL418 in subjects with solid tumors. XL418 is a new chemical entity that inhibits a spectrum of targets, including Akt and p70S6K, that mediate PI3 Kinase / PTEN signaling.
Conditions
Interventions
- DRUG
-
XL418
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-04-30
Countries
- United States
Study Locations
More Related Trials
-
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
NCT04797468 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase I Trial of PX-478
NCT00522652 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103 ·Status: RECRUITING ·Phase: PHASE1
-
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06630247 ·Status: TERMINATED ·Phase: PHASE1
-
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
NCT00796484 ·Status: TERMINATED ·Phase: PHASE1
-
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
NCT00692640 ·Status: COMPLETED ·Phase: PHASE1
-
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
NCT00336765 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
NCT00485719 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
NCT01859351 ·Status: TERMINATED ·Phase: PHASE1
-
Study of XL281 in Adults With Solid Tumors
NCT00451880 ·Status: COMPLETED ·Phase: PHASE1
-
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
NCT00591682 ·Status: SUSPENDED ·Phase: PHASE1
-
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
NCT02646852 ·Status: COMPLETED ·Phase: PHASE1
-
Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05474859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
NCT00350831 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of SLC-391 in Subjects With Solid Tumors
NCT03990454 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
XK469 in Treating Patients With Advanced Solid Tumors
NCT00028548 ·Status: COMPLETED ·Phase: PHASE1
-
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
NCT01239108 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
NCT00756847 ·Status: COMPLETED ·Phase: PHASE1
-
CHS 828 in Treating Patients With Solid Tumors
NCT00003979 ·Status: WITHDRAWN ·Phase: PHASE1
-
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
NCT01462175 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT03646071 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
NCT00997360 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
NCT03730142 ·Status: COMPLETED ·Phase: PHASE1